Trillium Asset Management’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Trillium Asset Management’s Portfolio FPRX Stock Details FPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-79,670	Closed	-$1.26M	–	246
2018 Q2	$1.26M	Buy	79,670 +448	+0.6%	+$7.82K	0.07%	175
2018 Q1	$1.36M	Buy	79,222 +20,220	+34%	+$394K	0.08%	169
2017 Q4	$1.29M	Sell	59,002 -5,894	-9%	-$190K	0.07%	170
2017 Q3	$2.65M	Sell	64,896 -399	-0.6%	-$12.5K	0.15%	138
2017 Q2	$1.97M	Buy	65,295 +955	+1%	+$29.8K	0.12%	147
2017 Q1	$2.33M	Sell	64,340 -275	-0.4%	-$12.1K	0.15%	141
2016 Q4	$3.24M	Buy	64,615 +751	+1%	+$39.5K	0.21%	124
2016 Q3	$3.35M	Buy	63,864 +1,419	+2%	+$67.8K	0.22%	124
2016 Q2	$2.58M	Buy	+62,445	New	+$2.72M	0.17%	141

Other funds holding FPRX

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Trillium Asset Management's FPRX Position: Q3 2018 in Review

Trillium Asset Management sold out of Five Prime Therapeutics, Inc. (FPRX) in Q3 2018, closing a stake of 79,670 shares — an estimated $1.26M sold.

Trillium Asset Management first reported a position in FPRX in Q2 2016 and held it in 9 quarters. The position peaked at $3.35M in Q3 2016. 114 funds tracked by Wall St. Rank hold FPRX as of Q3 2018.

Trillium Asset Management reported no remaining Five Prime Therapeutics, Inc. position as of Q3 2018 after selling out during the quarter.
Trillium Asset Management sold 79,670 Five Prime Therapeutics, Inc. shares in Q3 2018, an estimated $1.26M.
Trillium Asset Management first reported a position in Five Prime Therapeutics, Inc. in Q2 2016 and held it in 9 quarters.
Trillium Asset Management's Five Prime Therapeutics, Inc. position peaked at $3.35M in Q3 2016.
114 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q3 2018.

Based on Trillium Asset Management's 13F filing for Q3 2018, filed 9 Nov 2018.